Novel biochemical markers in suspected acute coronary syndrome: Systematic review and critical appraisal

Heart

Volumn 96, Issue 13, 2010, Pages 1001-1010

  Dekker, Marieke S ^a,b,c   Mosterd, Arend ^a,b   Van 'T Hof, Arnoud W J ^c   Hoes, Arno W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; GLYCOGEN PHOSPHORYLASE B; ISCHEMIA MODIFIED ALBUMIN; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; MYOGLOBIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; PREDICTION AND FORECASTING; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 77954284650     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.189886     Document Type: Review

References (105)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
3. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115:e356-75.
4. Pollack CV Jr, Braunwald E. 2007 Update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 2007.
5. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
6. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. The standards for reporting of diagnostic accuracy group. Croat Med J 2003;44:639-50.
7. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. AJR Am J Roentgenol 2003;181:51-5.
8. Moons KG, Harrell FE. Sensitivity and specificity should be de-emphasized in diagnostic accuracy studies. Acad Radiol 2003;10:670-2.
9. Moons KG, Biesheuvel CJ, Grobbee DE. Test research versus diagnostic research. Clin Chem 2004;50:473-6.
10. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36. (Pubitemid 12142173)
11. Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Heart 2001;85:133-42.
12. Aroney CN, Aylward P, Kelly A, et al. National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. Guidelines for the management of acute coronary syndromes. The Medical Journal of Australia 2006.
13. Findlay I, Newby D, Pedley D, et al. Acute coronary syndromes. A national clinical guideline. Scottisch Intercollegiate Guidelines Network 2007.
14. Delanghe JR, De Mol AM, De Buyzere ML, et al. Mass concentration and activity concentration of creatine kinase isoenzyme MB compared in serum after acute myocardial infarction. Clin Chem 1990;36:149-53.
15. Apple FS, Christenson RH, Valdes R Jr, et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem 1999;45:199-205.
16. Bock JL, Brogan GX Jr, McCuskey CF, et al. Evaluation of CK-MB isoform analysis for early diagnosis of myocardial infarction. J Emerg Med 1999;17:75-9.
17. Capellan O, Hollander JE, Pollack C Jr, et al. Prospective evaluation of emergency department patients with potential coronary syndromes using initial absolute CK-MB vs. CK-MB relative index. J Emerg Med 2003;24:361-7.
18. Castaldo AM, Ercolini P, Forino F, et al. Plasma myoglobin in the early diagnosis of acute myocardial infarction. Eur J Clin Chem Clin Biochem 1994;32:349-53. (Pubitemid 24164875)
19. Collinson PO, Gaze DC, Morris F, et al. Comparison of biomarker strategies for rapid rule out of myocardial infarction in the emergency department using ACC/ESC diagnostic criteria. Ann Clin Biochem 2006;43:273-80.
20. Esses D, Gallagher EJ, Iannaccone R, et al. Six-hour versus 12-hour protocols for AMI: CK-MB in conjunction with myoglobin. Am J Emerg Med 2001;19:182-6.
21. Fesmire FM, Percy RF, Bardoner JB, et al. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of +1.6ng/ml. Am Heart J 1998;136:237-44.
22. Fesmire FM. Delta CK-MB outperforms delta troponin I at 2 h during the ED rule out of acute myocardial infarction. Am J Emerg Med 2000;18:1-8.
23. Fesmire FM. A rapid protocol to identify and exclude acute myocardial infarction: continuous 12-lead ECG monitoring with 2-hour delta CK-MB. Am J Emerg Med 2000;18:698-702.
24. Fesmire FM, Christenson RH, Fody EP, et al. Delta creatine kinase-MB outperforms myoglobin at 2 h during the emergency department identification and exclusion of troponin positive non-ST-segment elevation acute coronary syndromes. Ann Emerg Med 2004;44:12-19.
25. Gerhardt W, Ljungdahl L, Herbert AK. Troponin-T CK MB (mass) in early diagnosis of ischemic myocardial injury. The Helsingborg Study, 1992. Clin Biochem 1993;26:231-40.
26. Gustafsson G, Dellborga M, Lindahl B, et al. Early diagnosis and exclusion of acute myocardial infarction by 2 h′ vector-ECG and determination of either myoglobin or CK-mb. BIOMACS-study. BIOchemical markers in acute coronary syndromes. Scand Cardiovasc J 2000;34:172-7.
27. Hedges JR, Young GP, Henkel GF, et al. Serial ECGs are less accurate than serial CK-MB results for emergency department diagnosis of myocardial infarction. Ann Emerg Med 1992;21:1445-50.
28. Kontos MC, Anderson FP, Hanbury CM, et al. Use of the combination of myoglobin and CK-MB mass for the rapid diagnosis of acute myocardial infarction. Am J Emerg Med 1997;15:14-19.
29. Kontos MC, Anderson FP, Schmidt KA, et al. Early diagnosis of acute myocardial infarction in patients without ST-segment elevation. Am J Cardiol 1999;83:155-8.
30. Polanczyk CA, Johnson PA, Cook EF, et al. A proposed strategy for utilization of creatine kinase-MB and troponin I in the evaluation of acute chest pain. Am J Cardiol 1999;83:1175-9.
31. Young GP, Gibler WB, Hedges JR, et al. Serial creatine kinase-MB results are a sensitive indicator of acute myocardial infarction in chest pain patients with nondiagnostic electrocardiograms: the second emergency medicine cardiac research group study. Acad Emerg Med 1997;4:869-77.
32. Brogan GX Jr, Friedman S, McCuskey C, et al. Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the emergency department. Ann Emerg Med 1994;24:665-71.
33. Collinson PO, Stubbs PJ, Kessler AC. Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice. Heart 2003;89:280-6.
34. Eggers KM, Oldgren J, Nordenskjold A, et al. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 2004;148:574-81.
35. Ellestad MH, Startt-Selvester R, Stanton E, et al. The utility of four biochemical markers in the triage of chest pain patients. Cardiology 2000;93:242-8.
36. Huggon AM, Chambers J, Nayeem N, et al. Biochemical markers in the management of suspected acute myocardial infarction in the emergency department. Emerg Med J 2001;18:15-19. (Pubitemid 34070831)
37. Jernberg T, Lindahl B, James S, et al. Comparison between strategies using creatine kinase-MB(mass), myoglobin, and troponin T in the early detection or exclusion of acute myocardial infarction in patients with chest pain and a nondiagnostic electrocardiogram. Am J Cardiol 2000;86:1367-71.
38. Jurlander B, Clemmensen P, Wagner GS, et al. Very early diagnosis and risk stratification of patients admitted with suspected acute myocardial infarction by the combined evaluation of a single serum value of cardiac troponin-T, myoglobin, and creatine kinase MB(mass). Eur Heart J 2000;21:382-9.
39. Mair J, Smidt J, Lechleitner P, et al. A decision tree for the early diagnosis of acute myocardial infarction in nontraumatic chest pain patients at hospital admission. Chest. 1995;108:1502-9.
40. McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001;104:1483-8.
41. Nagurney JT, Brown DF, Chae C, et al. The sensitivity of cardiac markers stratified by symptom duration. J Emerg Med 2005;29:409-15.
42. Ng SM, Krishnaswamy P, Morissey R, et al. Ninety-minute accelerated critical pathway for chest pain evaluation. Am J Cardiol 2001;88:611-17.
43. Penttila K, Koukkunen H, Halinen M, et al. Myoglobin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain. Clin Biochem 2002;35:647-53.
44. Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation 1999;99:1671-7.
45. Haastrup B, Gill S, Kristensen SR, et al. Biochemical markers of ischaemia for the early identification of acute myocardial infarction without ST segment elevation. Cardiology 2000;94:254-61. (Pubitemid 32402288)
46. Ruzgar O, Bilge AK, Bugra Z, et al. The use of human heart-type fatty acid-binding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatine kinase-myocardial band. Heart Vessels 2006;21:309-14.
47. Parikh SV, de Lemos JA. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 2006;332:186-97.
48. de Winter RJ, Koster RW, Sturk A, et al. Value of myoglobin, troponin T, and CKMBmass in ruling out an acute myocardial infarction in the emergency room. Circulation 1995;92:3401-7.
49. de Winter RJ, Lijmer JG, Koster RW, et al. Diagnostic accuracy of myoglobin concentration for the early diagnosis of acute myocardial infarction. Ann Emerg Med 2000;35:113-20.
50. Melanson SF, Lewandrowski EL, Januzzi JL, et al. Reevaluation of myoglobin for acute chest pain evaluation: would false-positive results on "first-draw" specimens lead to increased hospital admissions? Am J Clin Pathol 2004;121:804-8.
51. Ohman EM, Casey C, Bengtson JR, et al. Early detection of acute myocardial infarction: additional diagnostic information from serum concentrations of myoglobin in patients without ST elevation. Br Heart J 1990;63:335-8. (Pubitemid 20182177)
52. Stork TV, Wu AH, Muller-Bardorff M, et al. Diagnostic and prognostic role of myoglobin in patients with suspected acute coronary syndrome. North-Wurttemberg Infarction Study (NOWIS) group. Am J Cardiol 2000;86:1371-4.
53. Tucker JF, Collins RA, Anderson AJ, et al. Value of serial myoglobin levels in the early diagnosis of patients admitted for acute myocardial infarction. Ann Emerg Med 1994;24:704-8.
54. Alansari SE, Croal BL. Diagnostic value of heart fatty acid binding protein and myoglobin in patients admitted with chest pain. Ann Clin Biochem 2004;41:391-6.
55. Ishii J, Wang JH, Naruse H, et al. Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem 1997;43:1372-8.
56. Nakata T, Hashimoto A, Hase M, et al. Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 2003;99:96-104.
57. Okamoto F, Sohmiya K, Ohkaru Y, et al. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med 2000;38:231-8.
58. Seino Y, Ogata K, Takano T, et al. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. Am J Med 2003;115:185-90.
59. Zaninotto M, Mion MM, Novello E, et al. Analytical and clinical evaluation of a new heart-type fatty acid-binding protein automated assay. Clin Chem Lab Med 2006;44:1383-5.
60. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005;352:15-35.
61. Chan CP, Wan TS, Watkins KL, et al. Rapid analysis of fatty acid-binding proteins with immunosensors and immunotests for early monitoring of tissue injury. Biosens Bioelectron 2005;20:2566-80.
62. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004;97:187-98.
63. Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 2006;52:19-29.
64. Colli A, Josa M, Pomar JL, et al. Heart fatty acid binding protein in the diagnosis of myocardial infarction: where do we stand today? Cardiology 2007;108:4-10.
65. Alhashemi JA. Diagnostic accuracy of a bedside qualitative immunochromatographic test for acute myocardial infarction. Am J Emerg Med 2006;24:149-55.
66. Cavus U, Coskun F, Yavuz B, et al. Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndromes. J Natl Med Assoc 2006;98:1067-70.
67. Chan CP, Sanderson JE, Glatz JF, et al. A superior early myocardial infarction marker. Human heart-type fatty acid-binding protein. Z Kardiol 2004;93:388-97.
68. Chen L, Guo X, Yang F. Role of heart-type fatty acid binding protein in early detection of acute myocardial infarction in comparison with cTnI, CK-MB and myoglobin. J Huazhong Univ Sci Technolog Med Sci 2004;24:449-51 459.
69. Ecollan P, Collet JP, Boon G, et al. Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay. Int J Cardiol 2007;119:349-54.
70. Ghani F, Wu AH, Graff L, et al. Role of heart-type fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem 2000;46:718-19. (Pubitemid 30318431)
71. Glatz JF, van der Vusse GF, Simoons ML, et al. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta 1998;272:87-92.
72. Mad P, Domanovits H, Fazelnia C, et al. Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. QJM 2007;100:203-10.
73. Nagahara D, Nakata T, Hashimoto A, et al. Early positive biomarker in relation to myocardial necrosis and impaired fatty acid metabolism in patients presenting with acute chest pain at an emergency room. Circ J 2006;70:419-25.
74. Seino Y, Tomita Y, Takano T, et al. Office cardiologists cooperative study on whole blood rapid panel tests in patients with suspicious acute myocardial infarction: comparison between heart-type fatty acid-binding protein and troponin T tests. Circ J 2004;68:144-8.
75. Tanaka T, Sohmiya K, Kitaura Y, et al. Clinical evaluation of point-of-care-testing of heart-type fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. J Immunoassay Immunochem 2006;27:225-38.
76. Tsuji R, Tanaka T, Sohmiya K, et al. Human heart-type cytoplasmic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction. Int J Cardiol 1993;41:209-17.
77. Valle HA, Riesgo LG, Bel MS, et al. Clinical assessment of heart-type fatty acid binding protein in early diagnosis of acute coronary syndrome. Eur J Emerg Med 2008;15:140-4.
78. Christenson RH, Duh SH, Sanhai WR, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001;47:464-70.
79. Gidenne S, Ceppa F, Fontan E, et al. Analytical performance of the albumin cobalt binding (ACB) test on the Cobas MIRA plus analyzer. Clin Chem Lab Med 2004;42:455-61.
80. Abadie JM, Blassingame CL, Bankson DD. Albumin cobalt binding assay to rule out acute coronary syndrome. Ann Clin Lab Sci 2005;35:66-72.
81. Anwaruddin S, Januzzi JL Jr, Baggish AL, et al. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005;123:140-5.
82. Collinson PO, Gaze DC, Bainbridge K, et al. Utility of admission cardiac troponin and "Ischemia Modified Albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 2006;23:256-61.
83. Keating L, Benger JR, Beetham R, et al. The PRIMA study: presentation ischaemia-modified albumin in the emergency department. Emerg Med J 2006;23:764-8.
84. Lee YW, Kim HJ, Cho YH, et al. Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. Clin Chim Acta 2007;384:24-7.
85. Liyan C, Jie Z, Yonghua W, et al. Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal 2008;22:45-9.
86. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006;152:253-62.
87. Roy D, Quiles J, Aldama G, et al. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004;97:297-301.
88. Sinha MK, Roy D, Gaze DC, et al. Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29-34.
89. Collinson PO, Gaze DC. Ischaemia-modified albumin: clinical utility and pitfalls in measurement. J Clin Pathol 2008;61:1025-8.
90. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-9.
91. Heeschen C, Dimmeler S, Hamm CW, et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005;45:229-37.
92. Laterza OF, Cameron SJ, Chappell D, et al. Evaluation of pregnancy-associated plasma protein A as a prognostic indicator in acute coronary syndrome patients. Clin Chim Acta 2004;348:163-9. (Pubitemid 39209015)
93. Lund J, Qin QP, Ilva T, et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003;108:1924-6.
94. Qin QP, Laitinen P, Majamaa-Voltti K, et al. Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc J 2002;36:358-61.
95. Wittfooth S, Qin QP, Lund J, et al. Immunofluorometric point-of-care assays for the detection of acute coronary syndrome-related noncomplexed pregnancy-associated plasma protein A. Clin Chem 2006;52:1794-801.
96. Wittfooth S, Qin QP, Pettersson K. Performance of immunofluorometric point-ofcare assays for free pregnancy-associated plasma protein A detection in whole blood samples. Clin Chem Lab Med 2008;46:18-20.
97. Dominguez-Rodriguez A, breu-Gonzalez P, Garcia-Gonzalez M, et al. Circulating pregnancy-associated plasma protein A is not an early marker of acute myocardial infarction. Clin Biochem 2005;38:180-2.
98. Elesber AA, Lerman A, Denktas AE, et al. Pregnancy associated plasma protein-A and risk stratification of patients presenting with chest pain in the emergency department. Int J Cardiol 2007;117:365-9.
99. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998;272:79-86. (Pubitemid 28179619)
100. Mair J, Puschendorf B, Smidt J, et al. Early release of glycogen phosphorylase in patients with unstable angina and transient ST-T alterations. Br Heart J 1994;72:125-7.
101. Peetz D, Post F, Schinzel H, et al. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005;43:1351-8.
102. Rabitzsch G, Mair J, Lechleitner P, et al. Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995;41:966-78.
103. Altwegg LA, Neidhart M, Hersberger M, et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 2007;28:941-8.
104. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868-77.
105. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.